170 related articles for article (PubMed ID: 32130989)
1. The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure.
West TA; Pollard JD; Chandra M; Hui RL; Weintraub MR; King CM; Grimsrud CD; Lo JC
J Foot Ankle Surg; 2020; 59(2):269-273. PubMed ID: 32130989
[TBL] [Abstract][Full Text] [Related]
2. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
3. [Atypical fracture of metatarsal bone in a patient with multiple myeloma who was treated long-term with bisphosphonates].
Adam Z; Sprláková-Puková A; Chaloupka R; Krejčí M; Pour L; Král Z; Mayer J
Vnitr Lek; 2013 Nov; 59(11):1022-6. PubMed ID: 24279448
[TBL] [Abstract][Full Text] [Related]
4. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
5. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA
BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248
[TBL] [Abstract][Full Text] [Related]
6. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
[TBL] [Abstract][Full Text] [Related]
7. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.
Lo JC; Grimsrud CD; Ott SM; Chandra M; Hui RL; Ettinger B
Osteoporos Int; 2019 Dec; 30(12):2515-2520. PubMed ID: 31555883
[TBL] [Abstract][Full Text] [Related]
8. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
9. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
[TBL] [Abstract][Full Text] [Related]
10. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy.
Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B
Bone; 2016 Apr; 85():142-7. PubMed ID: 26769007
[TBL] [Abstract][Full Text] [Related]
11. Atypical femoral fractures related to bisphosphonate use: A comprehensive review of 19 patients.
Şahin K; Ergin ON; Bayram S; Akgül T
Ulus Travma Acil Cerrahi Derg; 2019 Nov; 25(6):603-610. PubMed ID: 31701502
[TBL] [Abstract][Full Text] [Related]
12. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY.
Bindon B; Adams W; Balasubramanian N; Sandhu J; Camacho P
Endocr Pract; 2018 Feb; 24(2):163-169. PubMed ID: 29144808
[TBL] [Abstract][Full Text] [Related]
13. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
[TBL] [Abstract][Full Text] [Related]
14. Diaphyseal femur fractures associated with bisphosphonate use.
Graham J; Irgit K; Smith WR; Bowen TR
Acta Orthop Traumatol Turc; 2013; 47(4):255-60. PubMed ID: 23999513
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.
Lim HS; Kim CK; Park YS; Moon YW; Lim SJ; Kim SM
J Bone Joint Surg Am; 2016 Dec; 98(23):1978-1987. PubMed ID: 27926679
[TBL] [Abstract][Full Text] [Related]
16. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
[TBL] [Abstract][Full Text] [Related]
17. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
18. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
Lee SH; Lee YH; Suh JS
AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
[TBL] [Abstract][Full Text] [Related]
19. Incidence of atypical nontraumatic diaphyseal fractures of the femur.
Dell RM; Adams AL; Greene DF; Funahashi TT; Silverman SL; Eisemon EO; Zhou H; Burchette RJ; Ott SM
J Bone Miner Res; 2012 Dec; 27(12):2544-50. PubMed ID: 22836783
[TBL] [Abstract][Full Text] [Related]
20. Atypical Fractures of the Femur Associated with Chronic Treatment with Bisphosphonates.
Fijewski G; Szostakowski B; Górski R; Modzelewski P; Dudek P; Małdyk P
Ortop Traumatol Rehabil; 2016 May; 18(3):239-249. PubMed ID: 28157080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]